Showing results (51-60 of 81) with videos related to
Sort By:
Pageof 9
Lancet (London, England)|April 11, 2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.Lancet (London, England)|September 13, 2005
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Neil R Poulter, Hans Wedel, Björn Dahlöf, et al.Lancet (London, England)|September 13, 2005
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Peter S Sever, Neil R Poulter, et al.Heart (British Cardiac Society)|August 20, 2018
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressureJoão Pedro Ferreira, Patrick Rossignol, Anne Pizard, et al.The New England Journal of Medicine|March 18, 2017
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S Sabatine, Robert P Giugliano, Anthony C Keech, et al.European Heart Journal|January 8, 2008
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closurePeter S Sever, Neil R Poulter, Bjorn Dahlof, et al.Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.Circulation|March 14, 2018
Inflammatory and Cholesterol Risk in the FOURIER TrialErin A Bohula, Robert P Giugliano, Lawrence A Leiter, et al.Pageof 9